From: A self-rating scale for patient-perceived side effects of inhaled corticosteroids
ICQ score | Increased ICS Dose (n = 21) | Decreased ICS Dose (n = 18) | Â | ||
---|---|---|---|---|---|
 | BL | 6M | BL | 6M | p-value* |
Total Score | 8 (3–26) | 16 (7–24) | 16 (8–28) | 11 (5–31) | 0.460 |
Voice Problems | 8 (2–25)†| 13 (4–37) | 14 (6–36) | 13 (2–22)†| 0.026 |
Oropharynx Problems | 24 (7–39) | 30 (11–42) | 29 (12–38) | 13 (6–33) | 0.330 |
Unpleasant Taste | 5 (0–25) | 17 (4–29) | 8 (0–20) | 5 (0–24) | 0.155 |
Skin, Hair and Nails | 7 (0–27) | 14 (1–33) | 23 (13–31) | 11 (4–36) | 0.064 |
Mood Problems | 6 (0–31) | 0 (0–22) | 3 (0–33) | 0 (0–19) | 0.455 |
Taste Disruption | 0 (0–28) | 6 (0–17) | 0 (0–18) | 0 (0–17) | 0.379 |
Perspiration | 17 (0–42) | 17 (0–42) | 17 (0–38)†| 17 (0–27) | 0.109 |
Oropharyngeal Itching | 0 (0–21) | 0 (0–17) | 0 (0–10) | 0 (0–19) | 0.533 |
Thirst | 17 (0–50)†| 25 (0–42) | 17 (0–29) | 13 (0–42) | 0.593 |
Tiredness | 17 (0–46) | 25 (0–33) | 33 (0–52) | 29 (0–52) | 0.465 |
Oral Candidiasis | 0 (0–17) | 0 (0–17) | 0 (0–33) | 0 (0–17) | 0.403 |
Facial Oedema | 0 (0–0) | 0 (0–17) | 0 (0–17) | 0 (0–0) | 0.056 |
Vision Deterioration | 0 (0–33) | 0 (0–33) | 0 (0–33) | 0 (0–17) | 0.756 |
Dental Deterioration | 0 (0–0) | 0 (0–17)†| 0 (0–17) | 0 (0–0)†| 0.185 |
Eye Dryness | 0 (0–17) | 0 (0–17) | 33 (0–50) | 17 (0–50) | 0.915 |